Naoto Ohi

635 total citations
19 papers, 519 citations indexed

About

Naoto Ohi is a scholar working on Molecular Biology, Organic Chemistry and Cancer Research. According to data from OpenAlex, Naoto Ohi has authored 19 papers receiving a total of 519 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 6 papers in Organic Chemistry and 4 papers in Cancer Research. Recurrent topics in Naoto Ohi's work include Cancer, Hypoxia, and Metabolism (4 papers), Synthesis and Reactions of Organic Compounds (4 papers) and Synthesis and biological activity (3 papers). Naoto Ohi is often cited by papers focused on Cancer, Hypoxia, and Metabolism (4 papers), Synthesis and Reactions of Organic Compounds (4 papers) and Synthesis and biological activity (3 papers). Naoto Ohi collaborates with scholars based in Japan, United States and Singapore. Naoto Ohi's co-authors include Norikazu Hashimoto, Fumihiko Hayakawa, T Naoe, Keiji Sugimoto, Shingo Kurahashi, Yasuo Harada, Yuji Nishikawa, Yasufumi Omori, Katsuhiko Enomoto and Takuo Tokairin and has published in prestigious journals such as Journal of Biological Chemistry, Blood and American Journal Of Pathology.

In The Last Decade

Naoto Ohi

19 papers receiving 510 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Naoto Ohi Japan 12 276 169 100 86 58 19 519
Young‐Choon Moon United States 10 451 1.6× 235 1.4× 140 1.4× 84 1.0× 28 0.5× 23 661
Teresa Carrascal Spain 9 332 1.2× 190 1.1× 66 0.7× 64 0.7× 43 0.7× 9 587
Shinji Oie Japan 12 315 1.1× 140 0.8× 88 0.9× 60 0.7× 38 0.7× 22 515
Christopher Toth United States 11 229 0.8× 211 1.2× 53 0.5× 57 0.7× 32 0.6× 15 586
Jennifer M. Shipman United States 11 378 1.4× 128 0.8× 123 1.2× 95 1.1× 17 0.3× 13 539
Mohammed Benkheil Belgium 8 245 0.9× 88 0.5× 80 0.8× 46 0.5× 65 1.1× 8 443
Mandy Beyer Germany 13 360 1.3× 120 0.7× 63 0.6× 40 0.5× 33 0.6× 19 557
Moacyr Oliveira United States 4 392 1.4× 237 1.4× 60 0.6× 40 0.5× 40 0.7× 4 593
Albert Liclican United States 10 254 0.9× 77 0.5× 43 0.4× 136 1.6× 33 0.6× 14 483
Mary Luz Uribe Spain 8 259 0.9× 153 0.9× 81 0.8× 45 0.5× 32 0.6× 14 513

Countries citing papers authored by Naoto Ohi

Since Specialization
Citations

This map shows the geographic impact of Naoto Ohi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Naoto Ohi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Naoto Ohi more than expected).

Fields of papers citing papers by Naoto Ohi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Naoto Ohi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Naoto Ohi. The network helps show where Naoto Ohi may publish in the future.

Co-authorship network of co-authors of Naoto Ohi

This figure shows the co-authorship network connecting the top 25 collaborators of Naoto Ohi. A scholar is included among the top collaborators of Naoto Ohi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Naoto Ohi. Naoto Ohi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
2.
3.
Eu, Jie Qing, Yaw Chyn Lim, Jayshree L. Hirpara, et al.. (2019). Evaluation of pharmacodynamic (PD) biomarkers in advanced cancer patients treated with oxidative phosphorylation (OXPHOS) inhibitor, OPC-317 (OPC). Annals of Oncology. 30. v174–v174. 1 indexed citations
4.
Hirpara, Jayshree L., Jie Qing Eu, Andrea Li‐Ann Wong, et al.. (2018). Metabolic reprogramming of oncogene-addicted cancer cells to OXPHOS as a mechanism of drug resistance. Redox Biology. 25. 101076–101076. 91 indexed citations
5.
Tolcher, Anthony W., Keith T. Flaherty, Geoffrey I. Shapiro, et al.. (2018). A First-in-Human Phase I Study of OPB-111077, a Small-Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers. The Oncologist. 23(6). 658–e72. 50 indexed citations
6.
Hayakawa, Fumihiko, Keiji Sugimoto, Yasuo Harada, et al.. (2013). A novel STAT inhibitor, OPB-31121, has a significant antitumor effect on leukemia with STAT-addictive oncokinases. Blood Cancer Journal. 3(11). e166–e166. 89 indexed citations
7.
8.
Nishikawa, Yuji, Naoto Ohi, Yuko Doi, et al.. (2009). Suppressive Effect of Orthovanadate on Hepatic Stellate Cell Activation and Liver Fibrosis in Rats. American Journal Of Pathology. 174(3). 881–890. 11 indexed citations
9.
Ohi, Naoto, Yuji Nishikawa, Takuo Tokairin, et al.. (2006). Maintenance of Bad Phosphorylation Prevents Apoptosis of Rat Hepatic Sinusoidal Endothelial Cells in Vitro and in Vivo. American Journal Of Pathology. 168(4). 1097–1106. 30 indexed citations
10.
Enomoto, Katsuhiko, Yuji Nishikawa, Yasufumi Omori, et al.. (2004). Cell biology and pathology of liver sinusoidal endothelial cells. PubMed. 37(4). 208–215. 55 indexed citations
11.
Ohi, Naoto, Akinori Tokunaga, Keiko Haraguchi, et al.. (1999). A novel adenovirus E1B19K-binding protein B5 inhibits apoptosis induced by Nip3 by forming a heterodimer through the C-terminal hydrophobic region. Cell Death and Differentiation. 6(4). 314–325. 41 indexed citations
12.
Matsuoka, Hirotaka, Naoki Kato, Naoto Ohi, et al.. (1997). Antirheumatic Agents. III. Novel Methotrexate Derivatives Bearing an Indoline Ring and a Modified Ornithine or Glutamic Acid.. Chemical and Pharmaceutical Bulletin. 45(7). 1146–1150. 11 indexed citations
13.
Nakajima, Takuma, Naoto Ohi, Takao Arai, et al.. (1996). Degradation of Topoisomerase IIα during Adenovirus E1A-induced Apoptosis Is Mediated by the Activation of the Ubiquitin Proteolysis System. Journal of Biological Chemistry. 271(40). 24842–24849. 48 indexed citations
14.
Matsuoka, Hirotaka, Hiroshi Suzuki, Toshio Kuroki, et al.. (1996). Antirheumatic Agents. II. Novel Methotrexate Derivatives Bearing an Alkyl-Substituted Benzene Ring.. Chemical and Pharmaceutical Bulletin. 44(12). 2287–2293. 3 indexed citations
15.
Yamaguchi, Masashi, Koji Kamei, Michitaka Akima, et al.. (1995). Novel Antiasthmatic Agents with Dual Activities of Thromboxane A2 Synthetase Inhibition and Bronchodilation. VI. Indazole Derivatives.. Chemical and Pharmaceutical Bulletin. 43(2). 332–334. 14 indexed citations
16.
Yamaguchi, Masashi, Koji Kamei, Michitaka Akima, et al.. (1995). Novel Antiasthmatic Agents with Dual Activities of Thromboxane A2 Synthetase Inhibition and Bronchodilation. V. Thienopyridazinone Derivatives.. Chemical and Pharmaceutical Bulletin. 43(2). 236–240. 34 indexed citations
17.
Nakajima, Tamie, Naoto Ohi, Tsutomu Arai, et al.. (1995). Adenovirus E1A-induced apoptosis elicits a steep decrease in the topoisomerase II alpha level during the latent phase.. PubMed. 10(4). 651–62. 21 indexed citations
18.
Yamaguchi, Masashi, Kaeko Kamei, Michitaka Akima, et al.. (1994). Novel Antiasthmatic Agents with Dual Activities of Thromboxane A2 Synthetase Inhibition and Bronchodilation. IV. 2-(2-(1-Imidazolyl)ethyl)-4-(3-pyridyl)-1(2H)-phthalazinones.. Chemical and Pharmaceutical Bulletin. 42(9). 1850–1853. 14 indexed citations
19.
Yamaguchi, Masashi, Koji Kamei, Michitaka Akima, et al.. (1994). Novel Antiasthmatic Agents with Dual Activities of Thromboxane A2 Synthetase Inhibition and Bronchodilation. III. 4-(2-(5-Ethyl-2-thienyl))-2'-(2-(1-imidazolyl)ethyl)-1(2H)-phthalazinones.. Chemical and Pharmaceutical Bulletin. 42(8). 1601–1604. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Young‐Choon Moon Breakdown of academic impact, for papers by Teresa Carrascal Breakdown of academic impact, for papers by Shinji Oie Breakdown of academic impact, for papers by Christopher Toth Breakdown of academic impact, for papers by Jennifer M. Shipman Breakdown of academic impact, for papers by Mohammed Benkheil Breakdown of academic impact, for papers by Mandy Beyer Breakdown of academic impact, for papers by Moacyr Oliveira Breakdown of academic impact, for papers by Albert Liclican Breakdown of academic impact, for papers by Mary Luz Uribe
Rankless by CCL
2026